ATMPs, Cell and Gene Therapies: Regulatory Landscape in US, EU and UK ATMPs, Cell and Gene Therapies: Regulatory Landscape in US, EU and UK As the field of advanced therapy medicinal products (ATMPs) continues to evolve, Regulatory Affairs (RA) professionals are called upon to navigate increasingly complex regulations, guidelines, and agency expectations regarding these therapies. This guide aims to thoroughly explain the regulatory landscape for ATMPs, cell and gene therapies within the major regions of the US, UK, and EU, emphasizing pharmacovigilance service provider obligations, special product regulatory pathways, and the interplay with CMC, clinical, and quality assurance (QA) teams….

Designing Clinical Development Pathways for Cell and Gene Therapies Designing Clinical Development Pathways for Cell and Gene Therapies Context Cell and gene therapies (CGTs) represent a significant advancement in the landscape of medicine, presenting novel opportunities for treating various diseases, including genetic disorders, cancers, and infectious diseases. The development of these advanced therapy medicinal products (ATMPs) requires meticulous planning and a thorough understanding of the regulatory frameworks governing their approval in major jurisdictions, specifically the US, the EU, and the UK. Regulatory Affairs professionals must navigate an array of guidelines and requirements designed to ensure patient safety, product efficacy, and…

CMC and Manufacturing Challenges in ATMP Regulatory Submissions CMC and Manufacturing Challenges in ATMP Regulatory Submissions Advanced Therapies Medicinal Products (ATMPs) represent a transformative area in biopharmaceuticals, encompassing gene therapies, somatic cell therapies, and tissue-engineered products. As these innovative therapies develop, the regulatory landscape continues to evolve. This article aims to elucidate the challenges within Chemistry, Manufacturing, and Controls (CMC) associated with ATMP regulatory submissions in the context of US, UK, and EU regulations. Regulatory Context for ATMPs The regulatory environment for ATMPs is critical to ensure patient safety, product efficacy, and overall market access. In the European Union, ATMPs…

Hospital Exemption, Early Access and Special Pathways for ATMPs Hospital Exemption, Early Access and Special Pathways for ATMPs Advanced Therapy Medicinal Products (ATMPs), including gene therapies, somatic cell therapies, and tissue-engineered products, represent a significant innovation in the treatment of various diseases. In this article, we will explore the regulatory landscape surrounding ATMPs, focusing on hospital exemptions, early access, and special pathways available in the US, UK, and EU. This manual aims to equip regulatory affairs professionals with a comprehensive understanding of applicable regulations, guidelines, and agency expectations relevant to the approval and commercialization of ATMPs. Context The rapid development…

Risk–Benefit Assessment for High-Risk Advanced Therapies Risk–Benefit Assessment for High-Risk Advanced Therapies In the ever-evolving landscape of regulatory affairs, the assessment of risk versus benefit in high-risk advanced therapies has become paramount. Particularly in the context of global pharmacovigilance and the special product regulatory pathways, understanding the frameworks established by regulatory bodies such as the FDA, EMA, and MHRA is essential for success. This article serves as a regulatory explainer manual, providing a structured examination of relevant regulations and guidelines, documentation expectations, review processes, and common deficiencies encountered by Regulators. Context Advanced Therapy Medicinal Products (ATMPs) include gene therapies, somatic…

Long-Term Follow-Up and Post-Authorisation Commitments for Gene Therapies Long-Term Follow-Up and Post-Authorisation Commitments for Gene Therapies Regulatory Affairs Context The advancement of gene therapy as a groundbreaking technology necessitates a robust framework to ensure patient safety, product efficacy, and compliance with regulatory expectations. Regulatory Affairs (RA) professionals play a pivotal role in navigating this evolving landscape, particularly regarding long-term follow-up and post-authorisation commitments mandated by regulatory authorities such as the FDA in the United States, the EMA in the European Union, and the MHRA in the United Kingdom. Gene therapies fall under the category of Advanced Therapy Medicinal Products (ATMPs)…

Case Studies: First-Generation ATMP Approvals and Their Regulatory Lessons Case Studies: First-Generation ATMP Approvals and Their Regulatory Lessons The advent of Advanced Therapy Medicinal Products (ATMPs), including gene therapies, somatic cell therapies, and tissue-engineered products, has revolutionized the landscape of therapeutics. These specialized product categories bring both promise and regulatory complexity. This article serves as a regulatory explainer manual, detailing the regulatory framework, agency expectations, and practical implications surrounding first-generation ATMP approvals in the US, UK, and EU. It aims to equip Regulatory Affairs (RA) professionals with essential insights for effective product compliance consulting. Regulatory Context for ATMPs ATMPs are…

Regulatory Expectations for Vector Design, Characterisation and Control Regulatory Expectations for Vector Design, Characterisation and Control This article provides an in-depth understanding of the regulatory framework surrounding vector design, characterisation, and control in the context of Advanced Therapy Medicinal Products (ATMPs), particularly cell and gene therapies. Targeting regulatory affairs professionals, the focus is on compliance with agencies like the FDA (United States), EMA (European Union), and MHRA (United Kingdom), while addressing critical interactions between regulatory affairs, CMC, clinical development, and pharmacovigilance solutions. Context Advanced therapy medicinal products (ATMPs) encompass a range of innovative therapies, including gene therapies, somatic cell therapies,…

Non-Clinical Packages for Cell and Gene Therapy Development Non-Clinical Packages for Cell and Gene Therapy Development Context Cell and gene therapies represent a paradigm shift in the treatment of various diseases, leveraging cutting-edge biotechnologies to modify or manipulate biological systems at the cellular level. As regulatory landscapes evolve, the field of Regulatory Affairs (RA) must navigate complex frameworks to ensure compliance with guidelines established by various global regulatory bodies, including the FDA, EMA, and MHRA. The regulatory oversight of Advanced Therapy Medicinal Products (ATMPs) examines the importance of carefully structured non-clinical data packages to support product development, safety, and efficacy…

Managing Comparability and Changes in ATMP Manufacturing Processes Managing Comparability and Changes in ATMP Manufacturing Processes Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, represent a novel category in the pharmaceutical landscape, necessitating a robust regulatory framework that ensures their safety, efficacy, and quality. This article serves as a comprehensive guide for regulatory affairs (RA) professionals, particularly focused on compliance regulatory affairs associated with managing comparability and changes in ATMP manufacturing processes. Regulatory Context ATMPs are defined by the European Medicines Agency (EMA) as therapies that are based on genes, tissues, or cells, and they have specific regulatory…